Want to see CH:MMTX full AI Analyst Report?
MMTX Stock Chart & Stats
CHF0.22
>-CHF0.01(-1.82%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.21 - CHF4.49
Previous CloseN/A
VolumeN/A
Average Volume (3M)252.50K
Market Cap
CHF34.12M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding159,102,450
10 Day Avg. Volume727,811
30 Day Avg. Volume252,501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)CHF5.50M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Very Low Financial LeverageExtremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.
Diversified Revenue/funding ModelA business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.
Bears Say
Persistent Negative ProfitabilityOngoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.
Negative Free Cash FlowNegative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.
Unprofitable With No Dividend SupportBeing unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.
RELIEF THERAPEUTICS Holding News
MMTX FAQ
What was RELIEF THERAPEUTICS Holding’s price range in the past 12 months?
RELIEF THERAPEUTICS Holding lowest stock price was CHF0.21 and its highest was CHF4.49 in the past 12 months.
What is RELIEF THERAPEUTICS Holding’s market cap?
RELIEF THERAPEUTICS Holding’s market cap is CHF34.12M.
When is RELIEF THERAPEUTICS Holding’s upcoming earnings report date?
RELIEF THERAPEUTICS Holding’s upcoming earnings report date is Sep 17, 2026 which is in 79 days.
How were RELIEF THERAPEUTICS Holding’s earnings last quarter?
Currently, no data Available
Is RELIEF THERAPEUTICS Holding overvalued?
According to Wall Street analysts RELIEF THERAPEUTICS Holding’s price is currently Undervalued.
Does RELIEF THERAPEUTICS Holding pay dividends?
RELIEF THERAPEUTICS Holding does not currently pay dividends.
What is RELIEF THERAPEUTICS Holding’s EPS estimate?
RELIEF THERAPEUTICS Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RELIEF THERAPEUTICS Holding have?
RELIEF THERAPEUTICS Holding has 159,102,450 shares outstanding.
What happened to RELIEF THERAPEUTICS Holding’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RELIEF THERAPEUTICS Holding?
Currently, no hedge funds are holding shares in CH:MMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RELIEF THERAPEUTICS Holding
MindMaze Therapeutics Holding SA creates and manages the MindMaze platform, which combines neuroscience with digital therapeutics to confront critical challenges in the field of neurology. Established in 2025, this company, headquartered in Lausanne, Switzerland, was previously named NeuroX Group SA.
Options Prices
Currently, No data available
---